Nuclera

Nuclera is a DNA synthesis company working on the synthesis of long DNA strands. Nuclera's water-based DNA synthesis and automation platform is based on engineered terminal deoxynucleotidyl transferases (TdT) to enable the production of gene and genome libraries. Their TdT enzymes incorporate reversibly terminating nucleotide triphosphates of the four nucleobases. Nuclera aims to provide long-length (longer than 500 nucleotides) variant DNA and genome libraries for protein, biological pathway, and genome-scale engineering.

Nuclera is driven by the mission to better human health by increasing accessibility to proteins. We are committed to providing rapid access to high-quality, soluble, active proteins at the benchtop allowing researchers to accelerate their protein projects, enabling faster success.

Using Nuclera’s eProtein Discovery™ system scientists can automate construct screening to inform off-platform protein scale-up, delivering reliable protein in-hand (µg-mg amounts) in less than 48 hours. Nuclera’s technology integrates cell-free protein synthesis and digital microfluidics on smart cartridges, allowing rapid progress on protein projects through a benchtop, automated, high-throughput protein access system.

Founded in 2013 by PhD students at the University of Cambridge, the company now has a presence in Cambridge, UK and Boston, MA employing over 100 employees.